
Overview
Champions Oncology fiscal Q4 revenue beats analyst expectations, per LSEG data
Adjusted EBITDA for fiscal Q4 beats consensus, reflecting operational efficiency
Fiscal 2025 revenue grows 14% yr/yr, driven by new data business
Outlook
Champions Oncology expects continued revenue growth in fiscal 2026
Company confident in further monetization of data offering
Champions sees strong pipeline heading into fiscal 2026
Result Drivers
DATA BUSINESS - New high-margin data business contributed $4.7 mln to annual revenue, driving overall growth
OPERATIONAL EFFICIENCY - Disciplined execution and operational improvements led to record adjusted EBITDA and reduced costs
MARKETING EXPENSES - Increased sales and marketing expenses due to expansion of data business development team and more conferences
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $12.30 mln | $12 mln (1 Analyst) |
Q4 EPS |
| -$0.13 |
|
Q4 Adjusted EBITDA | Beat | -$1.02 mln | -$2.48 mln (1 Analyst) |
Q4 Gross Margin |
| 41.0% |
|
Q4 Income from Operations | Beat | -$2 mln | -$3.23 mln (1 Analyst) |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 34.6% above its July 22 closing price of $7.85
The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 38 three months ago
Press Release: ID:nACSCgv63a